CNTBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Connect Biopharma Holdings Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.01 (-0.72%)
Close on Oct 19, 2026
- Market cap
- $56.58M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-90740.6%
Net margin
-86687.5%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -99.8% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -82.7% | |
| Return on assets | – | – | -70.5% | |
| Current ratio | – | – | 3.74 | |
| Interest coverage | – | – | – | |
| Capex to revenue | – | – | 678.1% | |
| Diluted shares | 17M | 17M | 56M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Connect Biopharma generated $308.40M from operations and spent $10.07M on capital expenditure, dividends and share buybacks. 94% of that went back into the business.
Generated
$308.40M
Used
$10.07M
Capital expenditure$9.50M94%Dividends$00%Share buybacks$566.00K6%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-86687.5%
×Asset turnover0.00×
×Equity multiplier1.17×
=Return on equity, FY2025-82.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -86687.5% | 0.00× | 1.17× | -82.7% |
| FY2024 | -60.0% | 0.23× | 1.18× | -16.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$55.48M
- Cash generatingOperating cash flow above zero-$51.21M
- Return on assets improvedROA up on the prior year-12.3% → -54.8%
- Earnings backed by cashOperating cash flow above net income-$51.21M vs -$55.48M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.46 → 3.74
- No dilutionShare count did not rise55M → 56M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.20 → 0.00